Supply Agreement Renewed for RosetteSep Reagent

An exclusive supply agreement for the RosetteSep reagent technology of StemCell Technologies (Vancouver, Canada) has been renewed by Applied Imaging Corp. (San Jose, CA, USA) for use in the isolation of circulating tumor cells in the blood of cancer patients.

The isolation and analysis of circulating tumor cells, often associated with metastatic cancer, may have clinical value for determining prognosis, response to therapy, or the most important monitoring strategies for certain cancers. The RosetteSep technique, based on StemCell's patented tetrameric antibody complex (TAC) technology, enriches circulating tumor cells directly from samples of cancer patients' blood. Combined with Applied Imaging's Ariol multiparameter cellular analysis system in preclinical trials in European cancer centers, the RosetteSep produced promising data on cancer cell detection.

Under the terms of the agreement, StemCell Technologies will exclusively supply Applied Imaging with RosetteSep tumor enrichment products and technology for clinical use in the isolation of tumor cells circulating in peripheral blood and their subsequent detection on an automated imaging platform. Applied Imaging can market, sell, and incorporate RosetteSep products into its own products.

"The successful development of a reproducible system to detect cancer cells in the blood could, without the painful extraction of patient's bone marrow cells, allow physicians to administer tests for multiple applications, including improved therapy selection, better monitoring of patient therapeutic responses, and rapid detection of disease recurrence,” said Carl Hull, CEO of Applied Imaging.




Related Links:
Applied Imaging
StemCell Technologies